🇺🇸 FDA

Drug profile · INN

epinephrine

NEFFY

approved C01CA24
US status
approved
Patents linked
5
News articles
1

Quick answer

epinephrine (NEFFY) is an FDA-listed pharmaceutical active ingredient. Associated with Ars Pharmaceuticals Irl Limited. Route of administration: intravenous, intraocular, intramuscular, subcuta. Current US regulatory status: approved.

Key facts

INN epinephrine
Brand NEFFY
Route INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTA
Formulation PATCH
ATC code C01CA24
Originator Ars Pharmaceuticals Irl Limited

Related patents

Search patents →

  1. US 12427121

    Enhanced delivery epinephrine compositions

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12023309

    Enhanced delivery epinephrine compositions

    Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11266611

    More potent and less toxic formulations of epinephrine and methods of medical use

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11191737

    Enhanced delivery epinephrine compositions

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8367734

    Stable epinephrine suspension formulation with high inhalation delivery efficiency

    Expires Mon Jan 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is epinephrine?

epinephrine (NEFFY) is an FDA-listed pharmaceutical active ingredient. Associated with Ars Pharmaceuticals Irl Limited. Route of administration: intravenous, intraocular, intramuscular, subcuta. Current US regulatory status: approved.

What is the brand name for epinephrine?

NEFFY is a marketed brand name for epinephrine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of epinephrine?

epinephrine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.